METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer

European Urology - Tập 71 - Trang 81-92 - 2017
Anwar R. Padhani1, Frederic E. Lecouvet2, Nina Tunariu3, Dow-Mu Koh3, Frederik De Keyzer4, David J. Collins3, Evis Sala5, Heinz Peter Schlemmer6, Giuseppe Petralia7, H. Alberto Vargas5, Stefano Fanti8, H. Bertrand Tombal9, Johann de Bono10
1Paul Strickland Scanner Centre, Mount Vernon Hospital, Middlesex, UK
2Department of Radiology, Centre du Cancer and Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
3Cancer Research UK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
4Department of Radiology, Medical Imaging Research Centre, University Hospitals Leuven, Leuven, Belgium
5Department of Radiology, Memorial Sloan-Kettering Cancer Centre, New York, NY, USA
6Department of Radiology, German Cancer Research Centre Heidelberg (DKFZ), Heidelberg, Germany
7Department of Radiology, European Institute of Oncology, Milan, Italy
8Service of Nuclear Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
9Department of Urology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
10Drug Development Unit, Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey, UK

Tài liệu tham khảo

Oudard, 2013, Progress in emerging therapies for advanced prostate cancer, Cancer Treat Rev, 39, 275, 10.1016/j.ctrv.2012.09.005

Body, 2015, Targeting bone metastases in prostate cancer: Improving clinical outcome, Nat Rev Urol, 12, 340, 10.1038/nrurol.2015.90

Sridhar, 2014, Castration-resistant prostate cancer: from new pathophysiology to new treatment, Eur Urol, 65, 289, 10.1016/j.eururo.2013.08.008

Fitzpatrick, 2014, Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel, Eur J Cancer, 50, 1617, 10.1016/j.ejca.2014.03.010

Gillessen, 2015, Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015, Ann Oncol, 26, 1589, 10.1093/annonc/mdv257

Halabi, 2016, Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer, J Clin Oncol, 10, 1652, 10.1200/JCO.2015.65.7270

Evans, 2016, The PREVAIL study: Primary outcomes by site and extent of baseline disease for enzalutamide-treated men with chemotherapy-naïve metastatic castration-resistant prostate cancer, Eur Urol, 1

Scher, 2016, Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the Prostate Cancer Clinical Trials Working Group 3, J Clin Oncol, 1

Padhani AR, Lecouvet FE, Tunariu N, et al. Rationale for modernizing imaging in advanced prostate cancer. Eur Urol Focus. In press.

Lecouvet, 2014, Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: A review and position statement by the European Organisation for Research and Treatment of Cancer imaging group, Eur J Cancer, 50, 2519, 10.1016/j.ejca.2014.07.002

Shen, 2014, Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis, Skeletal Radiol, 43, 1503, 10.1007/s00256-014-1903-9

Liu, 2015, Diagnostic performance of diffusion-weighted magnetic resonance imaging in bone malignancy, Medicine (Baltimore), 94, e1998, 10.1097/MD.0000000000001998

Taouli, 2016, Diffusion-weighted imaging outside the brain: Consensus statement from an ISMRM-sponsored workshop, J Magn Reson Imaging, 10.1002/jmri.25196

Spritzer, 2013, Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success, Radiology, 269, 816, 10.1148/radiol.13121782

Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 161, 1215, 10.1016/j.cell.2015.05.001

Tombal, 2005, Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases, Prostate, 65, 178, 10.1002/pros.20280

Lecouvet, 2011

Padhani, 2013, Assessing the relation between bone marrow signal intensity and apparent diffusion coefficient in diffusion-weighted MRI, AJR Am J Roentgenol, 200, 163, 10.2214/AJR.11.8185

Amlani, 2013, Relationships between diffusion weighted signal intensity, adc and water/fat content of malignant bone marrow, 3895

Koh, 2012, Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls, AJR Am J Roentgenol, 199, 252, 10.2214/AJR.11.7866

Moulopoulos, 2014

Vande Berg, 1998, Magnetic resonance imaging of normal bone marrow, Eur Radiol, 8, 1327, 10.1007/s003300050547

Pasoglou, 2013, One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): Toward an upfront simplified ‘all-in-one’ imaging approach?, Prostate, 74, 469, 10.1002/pros.22764

Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

Cookson, 2013, Castration-resistant prostate cancer: AUA guideline, J Urol, 190, 429, 10.1016/j.juro.2013.05.005

Halabi, 2014, Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer, J Clin Oncol, 32, 671, 10.1200/JCO.2013.52.3696

Parker, 2013, Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med, 369, 213, 10.1056/NEJMoa1213755

de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618

Beer, 2014, Enzalutamide in metastatic prostate cancer before chemotherapy, N Engl J Med, 371, 424, 10.1056/NEJMoa1405095

James, 2015, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 6736, 1

Ryan, 2015, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 16, 152, 10.1016/S1470-2045(14)71205-7

Dennis, 2012, Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer, J Clin Oncol, 30, 519, 10.1200/JCO.2011.36.5791

Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747

Ceci, 2016, 11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel, Eur J Nucl Med Mol Imaging, 43, 84, 10.1007/s00259-015-3177-4

Tait, 2014, Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival, BJU Int, 114, E70, 10.1111/bju.12717

Sabbatini, 1999, Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer, J Clin Oncol, 17, 948, 10.1200/JCO.1999.17.3.948

Perez-Lopez R, Lorente D, Blackledge MD, et al. Volume of bone metastasis assessed with whole-body diffusion-weighted imaging is associated with overall survival in metastatic castration-resistant prostate cancer. Radiology. In-press. http://dx.doi.org/10.1148/radiol.2015150799

Aparicio, 2013, Platinum-based chemotherapy for variant castrate-resistant prostate cancer, Clin Cancer Res, 19, 3621, 10.1158/1078-0432.CCR-12-3791

Morris, 2015, Radiographic Progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 Results, J Clin Oncol, 33, 1356, 10.1200/JCO.2014.55.3875

Sonpavde, 2015, Association between RECIST changes and survival in patients with metastatic castration-resistant prostate cancer receiving docetaxel, Eur Urol

Messiou, 2014, Use of apparent diffusion coefficient as a response biomarker in bone: effect of developing sclerosis on quantified values, Skeletal Radiol, 43, 205, 10.1007/s00256-013-1768-3

Messiou, 2011, Assessing response in bone metastases in prostate cancer with diffusion weighted MRI, Eur Radiol, 21, 2169, 10.1007/s00330-011-2173-8

Koh, 2009, Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial, Eur Radiol, 19, 2728, 10.1007/s00330-009-1469-4

Messiou, 2011, Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility, Eur Radiol, 21, 1713, 10.1007/s00330-011-2116-4

Thông tin
Thông tin xuất bản

European Urology

Tập 71

81-92

Thông tin tác giả